期刊文献+

检测尿Ⅰ型胶原交联氨基末端肽监测抗骨吸收药物疗效的特异性评价 被引量:5

Evaluation the specificity of urine-NTx in monitoring the effectiveness of antiresorptive therapy
暂未订购
导出
摘要 目的 研究检测尿I型胶原交联氨基末端肽 (NTx)监测抗骨吸收药物疗效的作用。方法 将 46名绝经后妇女随机分成治疗组 (阿仑磷酸钠 10mg/d ,6个月 )和对照组 (安慰剂 ,6个月 )。用ELISA法检测尿NTx值 ,双能X线骨密度仪测定腰椎骨密度。结果 治疗组和对照组的NTx和骨密度的改变率分别为 -5 1.64 %、5 %和 5 .16%、-2 .5 8%,治疗组的骨吸收指标均下降 ,以NTx下降最明显 ,近 5 1.4%(P <0 .0 0 1) ,对照组的NTx值却有所上升。 Objective To investigate the effect of urine NTx in monitoring the effects of treatment osteoporosis with anti resorption drugs.Methods 46 subjects were randomly divided into two groups, treated with oral Alendronate 10mg per day (28 cases) or placebo (18 cases), respectively, for 6 months.BMD of lumbar spine and urine NTx were analysed at the beginning and the end of the study.Results The change rate of BMD and urine NTx in the treatment and control group were 51.64%,5% and 16%,-2.58%;Markers of bone resorption were decreased after Alendronate therapy,urine NTx was signicificantly decreased to 51.4%( P <0.001), and there were increased in placebo group.Conclusions NTx would be used suitably to monitor the effects of antiresorptive treatment of osteoporosis.
出处 《临床内科杂志》 CAS 北大核心 2002年第5期359-361,共3页 Journal of Clinical Internal Medicine
基金 "九五"国家科技攻关资助项目( 96 90 6 0 5 0 6 )
关键词 绝经 骨矿盐密度 骨质疏松症 尿I型胶原交联氨基末端肽 Menopause Bone mineral density Osteoporosis Type I collagen cross linked N telopeptides in urine
  • 相关文献

参考文献8

  • 1Hanson DA, Weis MAE, Bollen AM, et al. A specific immunoassay for monitoring human bone resorption: Quantitation of type I collagen cross-linked N-telopeptides in urine. J Bone Miner Res,1992,7:1251-1258.
  • 2Gorai I, Taguchi Y, Chaki O, et al.Specific changes of urinary excretion of cross-linked N-telopeptides of type I collagen in pre-and post-menopausal women: Correlation with other markers of bone turnover. Calcif Tissue Int,1997,60:317-322.
  • 3Gertz BJ, Shao P, Wanson DA, et al.Monitoring bone resorption in early postmenopausal woman by an immunoassay for cross-linked collagen peptides in urine. J Bone Miner Res,1994,9:135-142.
  • 4Rosen HN, Moses AC, Garber J, et al.Vtility of biochemical markers of bone turnover in the follow-up of patients treatment with biphosphonates. Calcif Tissue Int,1998,63:363-368.
  • 5Rosen CJ, Chesnut CH,Mallinak NJS.The predictive value of biochemical markers of bone turnover for bone mineral density in early postmenopausal women treat with hormone replacement or calcium supplementation. J Clin Endocrinol Metab, 1997,82:1904-1910.
  • 6Taguchi Y, Gorai I, Zhang MG, et al.Difference in bone resorption after menopause in Japanese woman with normal or low bone mineral density:Quantitation of urinary cross-linked N-telopeptides. Calcil Tissue Int,1998,62:395-399.
  • 7Garnero P, Gineyts E, Arbault P, et al.Different effect of biphosphonate and estrogen therapy on free and peptided-bound bone cross-links excretion. J Bone Miner Res,1995,10:641-649.
  • 8Garnero P, Shih WJ, Arbault P, et al. Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporatic women in response to Alendronate treatment. J Clin Endocrinol Metab, 1994,79:1693-1700.

同被引文献42

引证文献5

二级引证文献32

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部